Myeloid-derived suppressor cells

General characteristics and relevance to clinical management of pancreatic cancer

P. Goedegebuure, J. B. Mitchem, M. R. Porembka, M. C B Tan, B. A. Belt, A. Wang-Gillam, W. E. Gillanders, W. G. Hawkins, D. C. Linehan

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC recruitment and maintenance in the tumor environment, strategies could be developed to reverse immune tolerance to tumor. We discuss here what is currently known about MDSC as well as some potential strategies targeting MDSC in the context of our work on pancreatic cancer and recent literature. Due to the number of new reports on MDSC, the most pertinent ones have been selected.

Original languageEnglish (US)
Pages (from-to)734-751
Number of pages18
JournalCurrent Cancer Drug Targets
Volume11
Issue number6
DOIs
StatePublished - Jul 2011

Fingerprint

Pancreatic Neoplasms
Neoplasms
Myeloid-Derived Suppressor Cells
Immunity
Active Immunotherapy
Arginase
Immune Tolerance
Tumor Microenvironment
Cell Lineage
Growth
Reactive Oxygen Species
Spleen
Bone Marrow
Maintenance

Keywords

  • Bone marrow
  • Immune suppression
  • Metastasis
  • Myeloid-derived suppressor cells
  • Pancreatic cancer

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Myeloid-derived suppressor cells : General characteristics and relevance to clinical management of pancreatic cancer. / Goedegebuure, P.; Mitchem, J. B.; Porembka, M. R.; Tan, M. C B; Belt, B. A.; Wang-Gillam, A.; Gillanders, W. E.; Hawkins, W. G.; Linehan, D. C.

In: Current Cancer Drug Targets, Vol. 11, No. 6, 07.2011, p. 734-751.

Research output: Contribution to journalArticle

Goedegebuure, P, Mitchem, JB, Porembka, MR, Tan, MCB, Belt, BA, Wang-Gillam, A, Gillanders, WE, Hawkins, WG & Linehan, DC 2011, 'Myeloid-derived suppressor cells: General characteristics and relevance to clinical management of pancreatic cancer', Current Cancer Drug Targets, vol. 11, no. 6, pp. 734-751. https://doi.org/10.2174/156800911796191024
Goedegebuure, P. ; Mitchem, J. B. ; Porembka, M. R. ; Tan, M. C B ; Belt, B. A. ; Wang-Gillam, A. ; Gillanders, W. E. ; Hawkins, W. G. ; Linehan, D. C. / Myeloid-derived suppressor cells : General characteristics and relevance to clinical management of pancreatic cancer. In: Current Cancer Drug Targets. 2011 ; Vol. 11, No. 6. pp. 734-751.
@article{2a950e835d6849f3a0fa0f90c61d91bf,
title = "Myeloid-derived suppressor cells: General characteristics and relevance to clinical management of pancreatic cancer",
abstract = "Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC recruitment and maintenance in the tumor environment, strategies could be developed to reverse immune tolerance to tumor. We discuss here what is currently known about MDSC as well as some potential strategies targeting MDSC in the context of our work on pancreatic cancer and recent literature. Due to the number of new reports on MDSC, the most pertinent ones have been selected.",
keywords = "Bone marrow, Immune suppression, Metastasis, Myeloid-derived suppressor cells, Pancreatic cancer",
author = "P. Goedegebuure and Mitchem, {J. B.} and Porembka, {M. R.} and Tan, {M. C B} and Belt, {B. A.} and A. Wang-Gillam and Gillanders, {W. E.} and Hawkins, {W. G.} and Linehan, {D. C.}",
year = "2011",
month = "7",
doi = "10.2174/156800911796191024",
language = "English (US)",
volume = "11",
pages = "734--751",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Myeloid-derived suppressor cells

T2 - General characteristics and relevance to clinical management of pancreatic cancer

AU - Goedegebuure, P.

AU - Mitchem, J. B.

AU - Porembka, M. R.

AU - Tan, M. C B

AU - Belt, B. A.

AU - Wang-Gillam, A.

AU - Gillanders, W. E.

AU - Hawkins, W. G.

AU - Linehan, D. C.

PY - 2011/7

Y1 - 2011/7

N2 - Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC recruitment and maintenance in the tumor environment, strategies could be developed to reverse immune tolerance to tumor. We discuss here what is currently known about MDSC as well as some potential strategies targeting MDSC in the context of our work on pancreatic cancer and recent literature. Due to the number of new reports on MDSC, the most pertinent ones have been selected.

AB - Recent studies describe a heterogeneous population of cells of the myeloid lineage, termed myeloid derived suppressor cells (MDSC), which are observed with increased prevalence in the peripheral blood and tumor microenvironment of cancer patients, including pancreatic cancer. Accumulation of MDSC in the peripheral circulation has been related to extent of disease, and correlates with stage. MDSC have primarily been implicated in promoting tumor growth by suppressing antitumor immunity. There is also compelling evidence MDSC are also involved in angiogenesis and metastatic spread. Two main subsets of MDSC have been identified in cancer patients: a monocytic subset, characterized by expression of CD14, and a granulocytic subset characterized by expression of CD15. Both subsets of MDSC actively suppress host immunity through a variety of mechanisms including production of reactive oxygen species and arginase. Just as in humans, accumulation of monocytic and granulocytic MDSC has been noted in the bone marrow, spleen, peripheral circulation, and tumors of tumor bearing mice. Successful targeting of MDSC in mice is associated with improved immune responses, delayed tumor growth, improved survival, and increased efficacy of vaccine therapy. By further elucidating mechanisms of MDSC recruitment and maintenance in the tumor environment, strategies could be developed to reverse immune tolerance to tumor. We discuss here what is currently known about MDSC as well as some potential strategies targeting MDSC in the context of our work on pancreatic cancer and recent literature. Due to the number of new reports on MDSC, the most pertinent ones have been selected.

KW - Bone marrow

KW - Immune suppression

KW - Metastasis

KW - Myeloid-derived suppressor cells

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=79959966013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959966013&partnerID=8YFLogxK

U2 - 10.2174/156800911796191024

DO - 10.2174/156800911796191024

M3 - Article

VL - 11

SP - 734

EP - 751

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 6

ER -